Boehringer Ingelheim has partnered with Gubra, a specialized biotech company and preclinical CRO that specializes in peptide-based drug discovery for metabolic diseases, to launch phase 1 clinical trials for BI 3034701
A few crackers or a small piece of toast is usually enough to protect your stomach without causing discomfort
The program provided clinical support (weekly check-ins, lab testing) to satisfy PA-type requirements, but purchases could be made outside traditional PBM channels
Tirzepatide vs Semaglutide : Final Verdict for 2026 By the clinical numbers, tirzepatide wins producing roughly 47% more average weight loss than semaglutide in the first-ever direct head-to-head comparison
Due to these reasons, manufacturers are charging higher prices
Even though only five per cent of users reported the side effect, it was enough to spread